Dr. Reddy's Laboratories Ltd. ADR Stock
Dr. Reddy's Laboratories Ltd. ADR gained 0.960% compared to yesterday.
Criterium "Brand" is seen as the biggest plus for Dr. Reddy's Laboratories Ltd. ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Dr. Reddy's Laboratories Ltd. ADR in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dr. Reddy's Laboratories Ltd. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. ADR | 0.960% | 0.962% | -7.895% | -11.017% | -10.256% | -83.846% | -80.556% |
| Sihuan Pharmaceutical Holdings Group Ltd. | -1.020% | 0.515% | 3.723% | -34.564% | -25.573% | 24.204% | -64.674% |
| Swedish Orphan Biovitrum Ab | -2.530% | 0.300% | -6.303% | 64.373% | 30.664% | 125.000% | 131.088% |
| Recordati SpA | -0.470% | 0.382% | 2.140% | 3.653% | 8.069% | 15.971% | -6.683% |
Comments
Dr. Reddy's Laboratories (RDY) was downgraded by The Goldman Sachs Group, Inc. from "neutral" to "sell".
Show more
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for RDY provided by MarketBeat
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $16.90 price target on the stock, up previously from $14.44.
Show more
Ratings data for RDY provided by MarketBeat
